Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphocyte Activation Gene-3 Protein (LAG-3)
- Target
- LAG-3
- Molecular classification
- Type I transmembrane protein, Immunoglobulin superfamily receptor, Immune checkpoint receptor
01
Overview
Lymphocyte activation gene-3 protein (LAG-3), also known as CD223, is an immune checkpoint receptor expressed on activated T cells, NK cells, and pDCs. It binds to MHC class II molecules, FGL1, and other ligands, negatively regulating T-cell activation and promoting T-cell exhaustion. LAG-3 is a therapeutic target in cancer immunotherapy and autoimmune diseases.
- Other names
- CD223Lymphocyte activating 3
02
Mechanism of action
LAG-3 blockade reinvigorates exhausted tumor-infiltrating lymphocytes and restores tolerance.
03
Biological functions
Negative regulation of T-cell activationPromotion of T-cell exhaustionRegulation of immune synapse formationInhibition of effector lymphocyte functionRegulation of immune responses
04
Disease associations
CancerAutoimmune diseasesChronic infection
05
Safety considerations
Immune-related adverse events (irAEs)Potential for autoimmunity
06
Interacting drugs
Monoclonal antibodies (anti-LAG-3)
1 more in the full profile.
07
Biomarkers
LAG-3 expression levels on immune cellsSoluble LAG-3 levels
Beyond the preview
Go deeper on Lymphocyte Activation Gene-3 Protein (LAG-3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lymphocyte Activation Gene-3 Protein (LAG-3).